Vaccitech Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Vaccitech's estimated annual revenue is currently $5.1M per year.
- Vaccitech's estimated revenue per employee is $102,000
- Vaccitech's total funding is $215.6M.
- Vaccitech has 50 Employees.
- Vaccitech grew their employee count by 35% last year.
- Vaccitech currently has 1 job openings.
What Is Vaccitech?
Vaccitech is a spin-out company from the University of Oxfordâ€™s Jenner institute, one of the oldest and most renowned vaccine research centres in the world. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The companyâ€™s protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. This autumn, Vaccitech will begin a phase IIB efficacy study for a universal influenza vaccine in the over 65 population, and an extended phase I prostate cancer trial.keywords:N/A